Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
New neurons continue forming in the brain’s hippocampus into old age
Study confirms presence of neural progenitor cells in adults
DNA carbon dating and single-nucleus RNA sequencing were used
Research shows variation in neuron production between individuals
Findings could aid treatments for neurodegenerative and psychiatric disorders
Human brain shows ongoing neuron formation into older age
A new study has confirmed that the human brain continues to produce new nerve cells well into late adulthood, challenging previous assumptions about age-related decline in neurogenesis. The findings, published in the journal Science, provide fresh insight into how adaptable the brain remains over a lifetime.
Neurogenesis, the process by which new neurons form in the brain, is known to occur in the hippocampus — a region involved in memory. While previous research has suggested that this process continues throughout life, there has been limited concrete evidence of the presence of neural progenitor cells in the adult brain.
Research confirms presence of progenitor cells
The study, conducted by researchers at the Karolinska Institutet in Sweden, confirms the existence of these progenitor cells — cells that develop into neurons — in the adult hippocampus. The team used DNA carbon dating to determine when the cells were formed. Brain tissue samples from people aged 0 to 78 were analysed, sourced from international biobanks.
“We have now been able to identify these cells of origin, which confirms that there is an ongoing formation of neurons in the hippocampus of the adult brain,” said Jonas Frisén, professor of stem cell research at the Karolinska Institutet, who led the study.
Advanced techniques reveal cell activity
To conduct the study, the researchers applied a method known as single-nucleus RNA sequencing, which allows scientists to analyse gene activity in individual cell nuclei. This was combined with machine learning to identify the different stages of neuron development, from stem cells to immature neurons.
The team identified all neural progenitor cell stages in early childhood samples. In adult samples, they located dividing progenitor cells using antibodies against the proliferation marker Ki67, alongside machine learning algorithms.
The results not only confirmed that adult neurogenesis takes place but also revealed that many of the dividing cells were in active developmental stages.
Significant variation between individuals
A notable finding from the study was the large variation in the presence of progenitor cells between individuals. While some adults had many such cells, others had very few. The researchers said this variability could have implications for understanding individual differences in brain ageing and cognitive resilience.
They also found that although the progenitor cells in humans were similar to those in animals such as mice, pigs, and monkeys, the active genes involved differed, suggesting some species-specific distinctions in brain development.
Implications for brain health and disease treatment
The findings provide valuable insight into how the human brain changes over time and could have medical implications. As many neurodegenerative diseases, such as Alzheimer’s, involve the loss of neurons in regions like the hippocampus, understanding how new neurons form could contribute to the development of regenerative therapies.
“This is an important piece of the puzzle in understanding how the human brain works and changes during life,” said Frisén. “It may also guide future treatment strategies for neurodegenerative and psychiatric conditions.”
Uterine cancer cases and deaths are projected to rise significantly in the US by 2050.
Black women are expected to experience the highest increase in incidence-based mortality.
A new model predicts incidence rising to 86.9 cases per 100,000 for Black women and 74.2 for White women.
Researchers stress the urgent need for improved prevention and early detection strategies.
Sharp increase in uterine cancer predicted over next three decades
Uterine cancer, currently the fourth most commonly diagnosed cancer among women in the United States, is projected to see a substantial rise in both cases and deaths by 2050, particularly among Black women. A new study led by researchers at Columbia University warns of worsening racial disparities in outcomes if preventative measures are not introduced.
This year alone, around 69,120 new cases of uterine cancer and nearly 14,000 deaths are expected in the United States. However, projections by the Columbia University research team, published in Cancer Epidemiology, Biomarkers & Prevention, indicate a significant increase in both incidence and mortality over the next 30 years.
Black women to face disproportionate increase in mortality
The study found that Black women already experience double the mortality rate from uterine cancer compared to women from other racial and ethnic backgrounds. Using a predictive model, researchers estimated that this gap will widen dramatically by 2050.
The incidence-based mortality rate among Black women is expected to rise from 14.1 per 100,000 in 2018 to 27.9 per 100,000 by 2050. In contrast, for White women, the rate will increase from 6.1 per 100,000 to 11.2 per 100,000 in the same period.
The incidence rate is also projected to rise to 86.9 cases per 100,000 in Black women and 74.2 cases per 100,000 in White women by 2050, compared to 56.8 and 57.7, respectively, in 2018.
About the study model
The projections were developed using the Columbia University Uterine Cancer Model (CU-UTMO), a state-transition microsimulation tool designed as part of the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET).
The model simulates the disease trajectory based on age (18–84), race (Black and White), tumour type (endometrioid or nonendometrioid), stage at diagnosis, and birth cohort from 1910 onwards. It was validated using 2018 data and showed a strong fit to actual incidence and mortality statistics.
Lead author Dr Jason D. Wright, the Sol Goldman Professor of Gynaecologic Oncology at Columbia University, explained:
“There are likely a number of factors that are associated with the increased burden of uterine cancer in Black women. They more commonly have aggressive types of uterine cancer, face delayed diagnosis resulting in later-stage disease at diagnosis, and there are often delays in their treatment.”
More aggressive tumour types in Black women
The model also highlighted that while endometrioid tumours, a less aggressive form, are projected to increase in both Black and White women, the rate of nonendometrioid tumours, which have a poorer prognosis, will rise considerably in Black women alone.
These trends point to an urgent need for improved public health interventions aimed at early diagnosis and treatment, as well as research into tailored approaches for high-risk groups.
Potential for prevention and screening
In a stress test of the model, researchers incorporated hypothetical screening methods capable of detecting uterine cancer and precancerous changes before clinical diagnosis. The analysis found that such interventions could lead to significant reductions in cancer incidence, lasting up to 15 years in White women and 16 years in Black women, if introduced at the age of 55.
Dr Wright commented on the implications of the test:
“The stress testing suggests that if there was an effective screening test, we may be able to substantially reduce the burden of disease. While there is presently no screening or prevention that is routinely used for uterine cancer, we are currently examining the potential impact of integrating screening into practice.”
Call for action
With cases and deaths from uterine cancer projected to climb, the researchers conclude that immediate steps must be taken to develop and implement primary and secondary prevention strategies. Without intervention, the burden of uterine cancer, particularly among Black women, is expected to grow significantly, posing serious public health challenges in the decades ahead.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
The authors acknowledged potential limitations in their findings
40% of participants in a new study said food affects their sleep
Dairy and sweets were linked to worse sleep and more disturbing dreams
Fruit, herbal tea and vegetables were associated with better sleep quality
Authors suggest that lactose intolerance may play a role in dream disturbance
A recent study has explored how food may influence sleep and dreaming, with some participants reporting that certain items — particularly dairy and sweets — disrupted their rest and contributed to nightmares.
Study looked at food, sleep and dreams
The research, published in the journal Frontiers in Psychology on Monday, analysed responses from 1,082 college-aged participants who completed online surveys between January and April 2023. The survey asked about over a dozen food categories, including dairy, meat, fruit, desserts, and spicy foods.
According to the findings, 40.2% of respondents said their eating habits had an impact on their sleep. About 25% stated that at least one food group made their sleep worse, while 20% said that some foods improved it.
Among the foods most commonly associated with disrupted sleep were dairy products (milk, yoghurt, cheese), desserts and sweets, and spicy dishes. On the other hand, fruit, vegetables, and herbal tea were most often credited with improving sleep quality.
Dairy and sweets linked to disturbing dreams
When asked about the effect of food on dreaming, 5.5% of participants said they noticed a link. Of those, 31% said desserts and sweets triggered nightmares, while 22% blamed dairy.
The study’s authors noted that while the data is based on self-reported experiences and may lack scientific proof, previous research does support the possibility that food can influence sleep patterns.
They added that the connection between dairy and negative dream experiences could be due to gastrointestinal symptoms in people with lactose intolerance, such as bloating or cramps, which may disrupt sleep and affect dream quality.
Limitations of the study
The authors acknowledged potential limitations in their findings. All participants were university students enrolled in psychology courses, meaning they may have had prior knowledge of related topics that could have influenced their responses.
Despite this, the research adds to a growing body of evidence suggesting that what we eat may affect not only how well we sleep, but how we dream.
Keep ReadingShow less
The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts
Amber heat-health alerts issued as temperatures approach 35°C in parts of the UK.
Early signs of heat stroke include confusion, slurred speech, and dizziness.
Heat exhaustion can develop into heat stroke if not treated within 30 minutes.
At-risk groups include the elderly, young children, and those with health conditions.
NHS and health experts urge people to stay hydrated, cool, and avoid midday sun.
Medical experts are urging the public to remain alert for the early signs of heat stroke, as temperatures across parts of England are expected to reach up to 35°C. The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts, warning that extreme heat can have serious health impacts. Doctors stress that symptoms can begin subtly, making early intervention crucial.
Heat alerts across multiple regions
Amber-level warnings are in effect for the West Midlands, East Midlands, Yorkshire and the Humber, South East, South West, London, and the East of England.
Dr Agostinho Sousa, Head of Extreme Events and Health Protection at UKHSA, said: “The temperatures we are likely to see over the next few days can result in serious health outcomes across the population.” He urged the public to take “sensible precautions while enjoying the sun”, and to look out for vulnerable individuals.
Recognising the early signs of heat stroke
Dr Javier Mateos Delgado, an emergency unit coordinator and expert in Family and Community Medicine, warned that heat stroke can begin with subtle neurological symptoms. These are often mistaken for tiredness or minor illness, delaying proper treatment.
According to Dr Delgado, early signs may include:
Slurred or incoherent speech
Irritability or mood changes
Disorientation or confusion
Loss of balance or blurred vision
He also noted that muscle cramps, especially at night or after exertion, despite drinking water, are a key warning sign. “The first symptoms are usually a feeling of intense heat, dizziness, and weakness,” he said. “You have to learn to listen to your body.”
When heat exhaustion becomes heat stroke
According to NHS guidance, heat exhaustion can be treated at home if the person is cooled down within 30 minutes. Signs include:
Dizziness
Nausea or vomiting
Headache
Sweating heavily
Weakness and tiredness
Muscle cramps
Fast breathing
Feeling very thirsty
However, if symptoms don’t improve within half an hour or worsen, it could indicate heat stroke, a life-threatening emergency.
Call 999 immediately if someone shows signs of heat stroke, which include:
Hot, dry skin that isn’t sweating
A high body temperature and flushed appearance
Rapid heartbeat
Confusion or unusual behaviour
Seizures
Loss of consciousness
While waiting for emergency services, move the person to a shaded or cool area, give them fluids if possible, and use water or cold items to help reduce their body temperature, especially on the neck and underarms.
Heat stroke prevention: What to do
Dr Mateos Delgado emphasised that prevention is often overlooked. “The problem is not usually that we don't know what to do,” he said, “but that we don't do it.”
To prevent heat stroke, experts recommend:
Avoiding strenuous activity during peak sunlight hours (11 am to 3 pm)
Staying indoors or in shaded areas during the hottest part of the day
Drinking water regularly—even if not thirsty
Wearing light, loose-fitting clothing
Using fans or keeping rooms cool by closing blinds and windows
Wearing sunglasses and sun hats, and applying sunscreen
Checking on friends, relatives, and neighbours, especially those at higher risk
Who is most at risk of heat stroke?
While anyone can be affected, certain groups are especially vulnerable to heat stroke. These include:
People over 65 or under 5 years old
Those with chronic illnesses such as heart disease, diabetes, or dementia
People on medications that affect sweating or body temperature
Those experiencing mental health challenges or substance misuse
People living alone, outdoors, or in poor housing conditions
Outdoor workers, including construction or farm labourers
Health officials urge everyone to take extra care over the coming days, as the UK experiences potentially record-breaking temperatures.
Understanding the signs and symptoms of heat stroke and acting quickly could help save lives during the ongoing heatwave.
Keep ReadingShow less
The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.
Keep ReadingShow less
Health officials expect the rollout to benefit around 220,000 adults over the next 3 years
NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
The programme aims to support 220,000 people over three years
Eligible patients must have a BMI over 40 and at least four obesity-related health issues
GP leaders raise concerns over increased workload
Pharmacists urge a broader weight management approach
NHS expands obesity treatment with Mounjaro
The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.
Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.
GPs express concern over added burden
While the rollout has been welcomed as a major step in tackling severe obesity, some family doctors have expressed concern over the operational challenges it may bring. The British Medical Association and other GP leaders have highlighted the need for additional training, resources and time to manage the expected rise in patient demand.
They warn that without extra support, the move could add further pressure to already stretched primary care services.
Calls for a comprehensive approach
Pharmacy experts and health professionals have stressed that Mounjaro should not be viewed as a standalone solution. Instead, they argue that it must be integrated into a broader weight management strategy that includes dietary changes, physical activity, and behavioural support.
There are also concerns about potential pressure on drug supplies as demand increases. Experts suggest that clear guidance on prescription protocols and supply management will be crucial to avoid shortages.
A targeted step in tackling obesity
The introduction of Mounjaro is part of the NHS’s wider effort to address rising obesity levels in the UK, which are closely linked to long-term health complications and increased strain on the health system. By targeting the most at-risk individuals, health officials hope the new measure will reduce future hospitalisations and improve overall health outcomes.